The dual role of IFN-γ in glioblastoma: from immune surveillance to immune escape

IFN-γ is a central effector node in immunotherapy. Recent studies suggest that the actual function of IFN-γ signaling depends on the combined effects of exposure duration, concentration gradient, glioblastoma (GBM) molecular subtype, and tumor microenvironment (TME) cellular composition, rather than on an intrinsic property of the cytokine itself. In GBM, chronic IFN-γ exposure drives lineage-dependent adaptive reprogramming, with mesenchymal-like and proneural-like cells exhibiting distinct patterns of signaling adaptation. These findings challenge a binary view of IFN-γ function and suggest that therapeutic strategies may need to extend beyond simple activation or blockade of this pathway.IFN-γ also influences macrophage polarization, regulatory T-cell function, NK-cell subset responses, and the expansion of myeloid-derived suppressor cells, while modulating antigen presentation, immunosuppression, and metabolic reprogramming within the TME. Together, these actions position IFN-γ as a convergence point bridging therapeutic response and adaptive resistance. However, the limited clinical efficacy of recombinant IFN-γ in GBM highlights the need for a more precise understanding of the temporal and context-dependent regulation of IFN-γ signaling. Strategies targeting IFN-γ-associated resistance mechanisms, including TNFRSF14 or JAK-STAT signaling and impaired NK-cell function, have been explored; however, a clear therapeutic rationale or contextual framework for targeting these pathways has yet to be established.Defining how IFN-γ switches between antitumor and protumor functions across GBM subtypes and treatment contexts may therefore be critical for the rational design of combination immunotherapies. In this review, we synthesize current evidence on IFN-γ signaling, its direct effects on GBM cells, its regulation of the immune microenvironment, and its translational implications, and propose a context-dependent framework for therapeutically targeting this pathway.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1985235
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The dual role of IFN-γ in glioblastoma: from immune surveillance to immune escape

Kun Luo, Xu Zhang, Wenjie Zhang, Jingxuan Xu et al.
5 links
Frontiers in Oncology
Glioma Diagnosis and Treatment
article

The dual role of IFN-γ in glioblastoma: from immune surveillance to immune escape

Kun Luo, Xu Zhang, Wenjie Zhang, Jingxuan Xu, Yan Yang, Qiang Sheng, Ruiyao Ma, Chang Ge
article en

Abstract

IFN-γ is a central effector node in immunotherapy. Recent studies suggest that the actual function of IFN-γ signaling depends on the combined effects of exposure duration, concentration gradient, glioblastoma (GBM) molecular subtype, and tumor microenvironment (TME) cellular composition, rather than on an intrinsic property of the cytokine itself. In GBM, chronic IFN-γ exposure drives lineage-dependent adaptive reprogramming, with mesenchymal-like and proneural-like cells exhibiting distinct patterns of signaling adaptation. These findings challenge a binary view of IFN-γ function and suggest that therapeutic strategies may need to extend beyond simple activation or blockade of this pathway.IFN-γ also influences macrophage polarization, regulatory T-cell function, NK-cell subset responses, and the expansion of myeloid-derived suppressor cells, while modulating antigen presentation, immunosuppression, and metabolic reprogramming within the TME. Together, these actions position IFN-γ as a convergence point bridging therapeutic response and adaptive resistance. However, the limited clinical efficacy of recombinant IFN-γ in GBM highlights the need for a more precise understanding of the temporal and context-dependent regulation of IFN-γ signaling. Strategies targeting IFN-γ-associated resistance mechanisms, including TNFRSF14 or JAK-STAT signaling and impaired NK-cell function, have been explored; however, a clear therapeutic rationale or contextual framework for targeting these pathways has yet to be established.Defining how IFN-γ switches between antitumor and protumor functions across GBM subtypes and treatment contexts may therefore be critical for the rational design of combination immunotherapies. In this review, we synthesize current evidence on IFN-γ signaling, its direct effects on GBM cells, its regulation of the immune microenvironment, and its translational implications, and propose a context-dependent framework for therapeutically targeting this pathway.

Frontiers in OncologyVol. 16
Xinjiang Medical University (CN), First Affiliated Hospital of Xinjiang Medical University (CN), Second Affiliated Hospital of Xinjiang Medical University (CN)
Xinjiang Medical University, Science and Technology Department of Xinjiang Uyghur Autonomous Region
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon